monetization_vector
recurring fees / product sales (mixed)
Medium
SEC-10K 0000313616-26-000062
pricing_architecture
tiered / negotiated (based on customer type and volume)
Medium
SEC-10K 0000313616-26-000062
target_gross_margin_bracket
59.1% Gross Margin (Strong (40-60%))
High
SEC-XBRL
revenue_model_type
subscription / transactional (mixed recurring and non-recurring product sales)
Medium
SEC-10K 0000313616-26-000062
customer_acquisition_metric
Direct sales force and independent distributors
Medium
SEC-10K 0000313616-26-000062
customer_segment_primary
enterprise (healthcare/pharmaceutical/research institutions)
Medium
SEC-10K 0000313616-26-000062
customer_segment_secondary
government / institutional research
Medium
SEC-10K 0000313616-26-000062
business_model_type_primary
manufacturer / B2B product company
Medium
SEC-10K 0000313616-26-000062
business_model_type_secondary
service provider (software, technical support, consulting)
Medium
SEC-10K 0000313616-26-000062
supply_chain_dependency
Moderate
Medium
SEC-10K 0000313616-26-000062
headcount_cost_structure
Linear
Medium
SEC-10K 0000313616-26-000062
geographic_footprint
Global (59% non-U.S., significant presence in Europe, Asia, high-growth markets)
Medium
SEC-10K 0000313616-26-000062
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
howey_test_risk_index
Low
Medium
SEC-10K 0000313616-26-000062
antitrust_exposure_flag
Yes
Medium
SEC-10K 0000313616-26-000062
data_sovereignty_risk
Moderate to High
Medium
SEC-10K 0000313616-26-000062
vendor_lock_dependency_score
Moderate
Medium
SEC-10K 0000313616-26-000062
pricing_power_rating
Moderate
Medium
SEC-10K 0000313616-26-000062
network_effect_present
Partial
Medium
SEC-10K 0000313616-26-000062
switching_cost_profile
High
Medium
SEC-10K 0000313616-26-000062
asset_efficiency_ratio
5.1% Return on Assets (Excellent)
High
SEC-XBRL
recession_resistance_tier
Mixed
Medium
SEC-10K 0000313616-26-000062
interest_rate_sensitivity
Moderate
Medium
SEC-10K 0000313616-26-000062
debt_leverage_profile
0.37x Total Debt / Equity (Conservative)
High
SEC-XBRL
geopolitical_supply_exposure
Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.
Medium
GICS-commodity-overlay-v2
marginal_cost_of_growth
Sublinear
Medium
SEC-10K 0000313616-26-000062
franchise_compliance_risk
N-A
Medium
SEC-10K 0000313616-26-000062
international_expansion_readiness
High
Medium
SEC-10K 0000313616-26-000062
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.25 (HIL — ~25% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v2
commodity_exposure_profile
Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.
Medium
GICS-commodity-overlay-v2
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
sec_cik
0000313616
High
SEC-EDGAR
ticker
DHR
High
SEC-EDGAR
capital_expenditure_profile
4.7% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
churn_vulnerability_index
Low to Moderate
Medium
SEC-10K 0000313616-26-000062
Filings_Dog_Scope
antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,churn_vulnerability_index,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,data_sovereignty_risk,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,marginal_cost_of_growth,monetization_vector,network_effect_present,pricing_architecture,pricing_power_rating,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,supply_chain_dependency,switching_cost_profile,vendor_lock_dependency_score
High
SEC-10K 0000313616-26-000062
insider_buys_6m
0
High
SEC-Form4 0000313616-26-000187..0000313616-26-000125
insider_sells_6m
4
High
SEC-Form4 0000313616-26-000187..0000313616-26-000125
insider_net_shares_6m
-59613
High
SEC-Form4 0000313616-26-000187..0000313616-26-000125
insider_last_transaction_date
2026-08-21
High
SEC-Form4 0000313616-26-000187..0000313616-26-000125
Insider_Dog_Checked
2026-10-03T13:46|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m
High
SEC-Form4 registry
activist_13d_count_1y
0
High
SEC-13D/G registry, subject-verified
blockholder_13g_count_1y
3
High
SEC-13D/G registry, subject-verified
activist_last_13d_date
none in window
High
SEC-13D/G registry, subject-verified